Related Experiment Video
Updated: Jul 14, 2026
08:28
Experimental Metastasis Assay
Published on: August 24, 2010
20.3K
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma
D Suwajanakorn1,2, A M Lane1, A K Go1
1Ocular Melanoma Center, Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Melanoma Research
|April 5, 2024
Summary
Gene expression profiling (GEP) did not significantly impact metastasis diagnosis or survival in uveal melanoma patients. Further advancements in detection methods and adjuvant therapies are needed to maximize GEP benefits.
Area of Science:
- Oncology
- Genetics
- Ophthalmology
Background:
- Gene expression profiling (GEP) guides surveillance for metastasis in uveal melanoma.
- The clinical utility of GEP in improving patient outcomes requires further evaluation.
Purpose of the Study:
- To assess the impact of GEP on the time to metastasis diagnosis, subsequent treatment, and survival in uveal melanoma patients.
Main Methods:
- A retrospective study compared 110 uveal melanoma patients with GEP to 110 matched controls without GEP.
- Outcomes including metastasis rates, overall survival, and melanoma-specific mortality were analyzed using Kaplan-Meier estimates.
Main Results:
- No significant differences were observed in the rates or time to metastasis diagnosis between GEP and no-GEP groups.
- Survival outcomes, including 5-year disease-specific survival and time to death from metastasis, showed no significant differences between the groups.
- GEP classification (1A, 1B, 2) did not correlate with significant differences in time to metastasis.
Conclusions:
- Current GEP, as applied in this study, did not demonstrate a significant benefit in improving metastasis diagnosis timing or survival outcomes for uveal melanoma.
- Enhanced metastasis detection techniques and effective adjuvant therapies are necessary to fully leverage the potential benefits of GEP in managing uveal melanoma.
